{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:56:18Z","timestamp":1780588578479,"version":"3.54.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.thromres.2025.109476","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T16:22:29Z","timestamp":1757607749000},"page":"109476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Efficacy and safety of reduced-dose versus full-dose direct oral anticoagulants for extended treatment of venous thromboembolism: A meta-analysis with trial sequential analysis and reconstructed time-to-event data"],"prefix":"10.1016","volume":"254","author":[{"given":"Ahmed","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Shalabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofian","family":"Zreigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman M.","family":"Tawfik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belal Mohamed","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Elsawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamas A.","family":"Mamas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"And\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Islam Y.","family":"Elgendy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Sabouret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2025.109476_bb0005","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1161\/CIRCRESAHA.115.306841","article-title":"Global burden of thrombosis: epidemiologic aspects","volume":"118","author":"Wendelboe","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.thromres.2025.109476_bb0010","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/eurheartj\/ehz236","article-title":"Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in Germany","volume":"41","author":"Keller","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2025.109476_bb0015","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.jacc.2020.07.070","article-title":"Antithrombotic management of venous thromboembolism: JACC focus seminar","volume":"76","author":"Renner","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2025.109476_bb0020","article-title":"Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis","volume":"366","author":"Khan","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.thromres.2025.109476_bb0025","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.thromres.2025.109476_bb0030","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2025.109476_bb0035","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2025.109476_bb0040","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"EINSTEIN Investigators","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2025.109476_bb0045","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.7326\/M21-1094","article-title":"Long-term risk for major bleeding during extended oral anticoagulant therapy for first unprovoked venous thromboembolism: a systematic review and meta-analysis","volume":"174","author":"Khan","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.thromres.2025.109476_bb0050","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0140-6736(24)02842-3","article-title":"Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial","volume":"405","author":"Couturaud","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2025.109476_bb0055","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1182\/bloodadvances.2023010177","article-title":"American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing","volume":"7","author":"Middeldorp","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.thromres.2025.109476_bb0060","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"Farge","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.thromres.2025.109476_bb0065","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update","volume":"41","author":"Key","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2025.109476_bb0070","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline","volume":"34","author":"Falanga","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.thromres.2025.109476_bb0075","doi-asserted-by":"crossref","DOI":"10.31083\/j.rcm2511406","article-title":"Thromboembolism in patients with cancer: a practical guide to recurrent events","volume":"25","author":"Kozhukhov","year":"2024","journal-title":"Rev. Cardiovasc. Med."},{"key":"10.1016\/j.thromres.2025.109476_bb0080","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/ehjcvp\/pvaa067","article-title":"Efficacy and safety of direct oral anticoagulants vs. low molecular weight heparin for cancer-related venous thromboembolism: a meta-analysis of randomized trials","volume":"7","author":"Elbadawi","year":"2021","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"10.1016\/j.thromres.2025.109476_bb0085","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa2416112","article-title":"Extended reduced-dose apixaban for cancer-associated venous thromboembolism","volume":"392","author":"Mah\u00e9","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2025.109476_bb0090","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.thromres.2025.109476_bb0095","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.thromres.2025.109476_bb0100","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.thromres.2025.109476_bb0105","series-title":"Analyzing Data and Undertaking Meta-Analyses","first-page":"257","article-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2019"},{"key":"10.1016\/j.thromres.2025.109476_bb0110","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.thromres.2025.109476_bb0115","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.thromres.2025.109476_bb0120","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2288-9-86","article-title":"Estimating required information size by quantifying diversity in random-effects model meta-analyses","volume":"9","author":"Wetterslev","year":"2009","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.thromres.2025.109476_bb0125","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jclinepi.2019.03.012","article-title":"The statistical significance of meta-analyses is frequently fragile: definition of a fragility index for meta-analyses","volume":"111","author":"Atal","year":"2019","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.thromres.2025.109476_bb0130","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.thromres.2025.109476_bb0135","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2025.109476_bb0140","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2025.109476_bb0145","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jtha.2024.03.011","article-title":"Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial","volume":"22","author":"McBane","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2025.109476_bb0150","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.thromres.2025.109476_bb0155","first-page":"S24","article-title":"Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban","volume":"29","author":"Gong","year":"2013","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.thromres.2025.109476_bb0160","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1080\/17425255.2018.1530213","article-title":"Pharmacokinetics of new oral anticoagulants: implications for use in routine care","volume":"14","author":"Ingrasciotta","year":"2018","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.thromres.2025.109476_bb0165","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1182\/asheducation-2013.1.471","article-title":"Risk assessment for recurrence and optimal agents for extended treatment of venous thromboembolism","volume":"2013","author":"Agnelli","year":"2013","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.thromres.2025.109476_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102194","article-title":"The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review and meta-analysis","volume":"64","author":"van Hylckama Vlieg","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.thromres.2025.109476_bb0175","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1053\/j.seminhematol.2014.02.002","article-title":"Direct oral anticoagulants and bleeding risk (in comparison to vitamin K antagonists and heparins), and the treatment of bleeding","volume":"51","author":"Palareti","year":"2014","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.thromres.2025.109476_bb0180","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/jth.14156","article-title":"Reduced-dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta-analysis","volume":"16","author":"Vasanthamohan","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2025.109476_bb0185","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s44313-024-00029-3","article-title":"Proper application of anticoagulation therapy on cancer-associated venous thrombosis","volume":"59","author":"Yhim","year":"2024","journal-title":"Blood Res."},{"key":"10.1016\/j.thromres.2025.109476_bb0190","first-page":"8547","article-title":"Anticoagulation and bleeding in the cancer patient","volume":"30","author":"Escobar","year":"2022","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.thromres.2025.109476_bb0195","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/2582923","article-title":"Cancer-associated thrombosis: not all low-molecular-weight heparins are the same, focus on tinzaparin, a narrative review","volume":"2022","author":"Fioretti","year":"2022","journal-title":"Int. J. Clin. Pract."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384825002269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384825002269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:40:16Z","timestamp":1762249216000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384825002269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":39,"alternative-id":["S0049384825002269"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109476","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of reduced-dose versus full-dose direct oral anticoagulants for extended treatment of venous thromboembolism: A meta-analysis with trial sequential analysis and reconstructed time-to-event data","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109476","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109476"}}